News
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Race and Rhythm make their moves to advance Australian share
Health & Biotech
Knocking heads: Incannex achieves key concussion breakthrough
News
Closing Bell: Sophie Ellis-Bextor was right, it really is murder on the dance floor
Health & Biotech
With $40m in the bank and an exciting product suite, Incannex targets game-changing US acquisition for even more growth
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
News
Closing Bell: Small caps lower in mindless, choppy trade
Health & Biotech
Incannex secures landmark deal, reinforcing position as a global medicinal cannabis and psychedelic powerhouse
Health & Biotech
ASX Health Stocks: 2 immunotherapy biotechs announce progress on clinical trials
News
Weed Week: New Yorkers with cannabis convictions first in line for retail licences, CBX Stock Exchange launches
Health & Biotech
The only game in town: Incannex announces big clinical trial results – IHL-42X drug reduced key obstructive sleep apnoea diagnostic measure by up to 91.5%
Health & Biotech
No worries: Severe anxiety disorders to get the Incannex, Monash Uni treatment via psychedelics within virtual reality
Health & Biotech
ASX Health Stocks: Avita to start selling RECELL across the US to treat extensive burns
Health & Biotech
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
News
February Winners: From rate hikes to military strikes, these ASX microcaps forged ahead
Health & Biotech
Incannex hits the Nasdaq for a wider audience
News
Closing Bell: CPI jitters strike again, while a mining story 33 years in the making sent one small cap surging
Health & Biotech